Brookline on Moderna (MRNA): 'Australia Authorizes RSV Vaccine,mRNA-1345 for Adults 60 Years and Older; Supports Our Outlook'
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $212.00 price target on Moderna (NASDAQ: MRNA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
